These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 35211872

  • 1. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA.
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [Abstract] [Full Text] [Related]

  • 2. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, Miller C, Penner N.
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [Abstract] [Full Text] [Related]

  • 3. Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
    Bowen JD, Stulc J, Hunter SF, Chen H, Lewin JB, Scaramozza M, Bozin I, Then Bergh F.
    Adv Ther; 2024 Aug; 41(8):3396-3406. PubMed ID: 38878121
    [Abstract] [Full Text] [Related]

  • 4. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS, EVOLVE-MS-2 Study Group.
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [Abstract] [Full Text] [Related]

  • 5. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S.
    Mult Scler; 2023 Dec; 29(14):1795-1807. PubMed ID: 37905526
    [Abstract] [Full Text] [Related]

  • 6. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [Abstract] [Full Text] [Related]

  • 7. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M, Roman C, Singer BA, Schmidt H, Thomas J, Shankar SL, Lyons J, Kapadia S.
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [Abstract] [Full Text] [Related]

  • 8. Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
    Hunter SF, Lindsey JW, Osborne B, Schreiber B, Branco F, Levin S, Lewin JB, Scaramozza M, Tian Z, Antezana A.
    Mult Scler Relat Disord; 2024 Nov; 91():105912. PubMed ID: 39393172
    [Abstract] [Full Text] [Related]

  • 9. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, de Seze J, Repovic P, Chen H, Hanna J, Messer J, Miller C, Naismith RT.
    Ther Adv Neurol Disord; 2021 Nov; 14():1756286421993999. PubMed ID: 33796143
    [Abstract] [Full Text] [Related]

  • 10. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E, Sejbaek T.
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [Abstract] [Full Text] [Related]

  • 12. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS.
    CNS Drugs; 2023 May; 37(5):441-452. PubMed ID: 37155132
    [Abstract] [Full Text] [Related]

  • 13. Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
    Liseno J, Lager B, Miller C, Shankar SL, Mendoza JP, Lewin JB.
    Neurol Ther; 2021 Jun; 10(1):349-360. PubMed ID: 33846959
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.
    Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
    J Comp Eff Res; 2024 Oct; 13(10):e230161. PubMed ID: 39158844
    [Abstract] [Full Text] [Related]

  • 15. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP, Wu L, Balshi A, Jun C, Baber U, Sloane JA.
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [Abstract] [Full Text] [Related]

  • 16. Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis.
    Lager B, Liseno J, Božin I, England SM, Shankar SL, Mendoza JP, Lewin JB.
    Neurol Ther; 2023 Feb; 12(1):145-159. PubMed ID: 36334241
    [Abstract] [Full Text] [Related]

  • 17. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H, Niino M, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S.
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [Abstract] [Full Text] [Related]

  • 18. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use.
    Paik J.
    CNS Drugs; 2021 Jun; 35(6):691-700. PubMed ID: 34057708
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP.
    Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
    [Abstract] [Full Text] [Related]

  • 20. Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
    Singer BA, Wray S, Gudesblatt M, Bumstead B, Ziemssen T, Bonnell A, Scaramozza M, Levin S, Shanmugasundaram M, Chen H, Mendoza JP, Lewin JB, Shankar SL.
    Neurol Ther; 2024 Aug; 13(4):1273-1285. PubMed ID: 38935202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.